Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Francesca Ponziani and Antonio Gasbarrini.
Francesca Ponziani
Connection Strength
7.646
Antonio Gasbarrini
  1. Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. Gastroenterology. 2021 04; 160(5):1891-1893.
    View in: PubMed
    Score: 0.921
  2. Sarcopenia in Patients with Advanced Liver Disease. Curr Protein Pept Sci. 2018; 19(7):681-691.
    View in: PubMed
    Score: 0.749
  3. Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time? Dig Dis Sci. 2017 09; 62(9):2220-2222.
    View in: PubMed
    Score: 0.731
  4. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017 Jul 07; 23(25):4491-4499.
    View in: PubMed
    Score: 0.724
  5. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017 Mar 08; 9(7):352-367.
    View in: PubMed
    Score: 0.707
  6. Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. Mediterr J Hematol Infect Dis. 2009 Dec 30; 1(3):e2009033.
    View in: PubMed
    Score: 0.430
  7. Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. Dig Liver Dis. 2021 05; 53(5):541-544.
    View in: PubMed
    Score: 0.233
  8. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020 12; 24(24):13072-13088.
    View in: PubMed
    Score: 0.229
  9. Letter: liver involvement and mortality in COVID-19 patients - authors' reply. Aliment Pharmacol Ther. 2020 Oct; 52(7):1264-1265.
    View in: PubMed
    Score: 0.226
  10. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. Aliment Pharmacol Ther. 2020 09; 52(6):1060-1068.
    View in: PubMed
    Score: 0.224
  11. NAFLD or comorbidities, that is the question. J Hepatol. 2020 09; 73(3):723.
    View in: PubMed
    Score: 0.220
  12. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019; 11:1758835919848184.
    View in: PubMed
    Score: 0.206
  13. Gut microbiota and aging. Eur Rev Med Pharmacol Sci. 2018 11; 22(21):7404-7413.
    View in: PubMed
    Score: 0.198
  14. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther. 2018 12; 48(11-12):1301-1311.
    View in: PubMed
    Score: 0.198
  15. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology. 2019 01; 69(1):107-120.
    View in: PubMed
    Score: 0.194
  16. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018 Jul; 12(7):641-656.
    View in: PubMed
    Score: 0.193
  17. Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol. 2018 May; 11(5):519-524.
    View in: PubMed
    Score: 0.190
  18. A novel ultrasound-based vascular calcification score (CALCS) to detect subclinical atherosclerosis. Eur Rev Med Pharmacol Sci. 2018 02; 22(3):736-742.
    View in: PubMed
    Score: 0.188
  19. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol. 2017 Dec 28; 9(36):1322-1331.
    View in: PubMed
    Score: 0.187
  20. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. Am J Kidney Dis. 2017 Aug; 70(2):297-300.
    View in: PubMed
    Score: 0.177
  21. Post-liver transplant intrahepatic cholestasis: etiology, clinical presentation, therapy. Eur Rev Med Pharmacol Sci. 2017 03; 21(1 Suppl):23-36.
    View in: PubMed
    Score: 0.177
  22. Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. Aliment Pharmacol Ther. 2020 Sep; 52(5):902-903.
    View in: PubMed
    Score: 0.056
  23. Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients. Biol Proced Online. 2020; 22:18.
    View in: PubMed
    Score: 0.056
  24. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019 02; 51(2):190-205.
    View in: PubMed
    Score: 0.050
  25. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2018 12; 25(12):1493-1500.
    View in: PubMed
    Score: 0.049
  26. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutr Metab Cardiovasc Dis. 2018 04; 28(4):369-384.
    View in: PubMed
    Score: 0.046
  27. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci. 2017 03; 21(1 Suppl):122-134.
    View in: PubMed
    Score: 0.044
  28. Liver transplantation for drug-induced acute liver failure. Eur Rev Med Pharmacol Sci. 2017 03; 21(1 Suppl):37-45.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.